Merck & Co., Inc: Papillomavirus Infections trials
The registry lists 38 Papillomavirus Infections studies with Merck & Co., Inc as lead sponsor. 1 are open to participants now and 26 have results posted.
Phase 1 1Phase 2 5Phase 3 26No phase 6(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Clinical Study of V503 in Chinese Females Who Have Previously Received a Bivalent Human Papillomavirus (HPV) Vaccine (V503-108)RecruitingNCT07785843Phase 3
- Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)CompletedNCT05119855Phase 3Results posted
- Immunogenicity and Safety of the 9-valent Human Papillomavirus (9vHPV) Vaccine in Japanese Boys and Girls (V503-066)CompletedNCT04772534Phase 3Results posted
- Immunobridging Study of 9- Valent Human Papillomavirus (9vHPV) Vaccine (V503) in Chinese Females 9 to 45 Years of Age (V503-024)CompletedNCT03903562Phase 3Results posted
- Safety and Immunogenicity Study of V503 (GARDASIL™9, 9vHPV Vaccine) Administered to 9- to 26-Year-Old Females and Males in Vietnam (V503-017)CompletedNCT03546842Phase 3Results posted
- Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004)CompletedNCT03158220Phase 3Results posted
- A Study to Compare Immune Response of V503 to Gardasil in 16- to 26-year-old Men (V503-020)CompletedNCT02114385Phase 3Results posted
- A Phase III Study of a 2-dose Regimen of a Multivalent Human Papillomavirus (HPV) Vaccine (V503), Administered to 9 to 14 Year-olds and Compared to Young Women, 16 to 26 Years Old (V503-010)CompletedNCT01984697Phase 3Results posted
- A Study of the Safety, Tolerability, and Immunogenicity of a 9-valent Human Papillomavirus Vaccine ([9vHPV]; V503) Administered to 9- to 15-Year-Old Japanese Girls (V503-008).CompletedNCT01254643Phase 3Results posted
- GARDASIL™ Study in Healthy Females Between 9 and 26 Years of Age in Sub-Saharan Africa (V501-046)CompletedNCT01245764Phase 3Results posted
- Observational Surveillance Study to Detect Potential Safety Signals in Patients Who Have Had at Least One Dose of GARDASIL™ (V501-031)CompletedNCT01078220Results posted
- GARDASIL™ Vaccine Impact in Population Study (V501-033)CompletedNCT01077856Results posted
- A Study of V503 Vaccine Given Concomitantly With REPEVAX™ in 11 to 15 Year Olds (V503-007)CompletedNCT01073293Phase 3Results posted
- GARDASIL Reexamination Study (V501-059)CompletedNCT01062074Results posted
- A Study of V503 Given Concomitantly With Menactra™ and Adacel™ in 11 to 15 Year Olds (V503-005)CompletedNCT00988884Phase 3Results posted
- A Study of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (V503-002)CompletedNCT00943722Phase 3Results posted
- Prevention of Human Papillomavirus (HPV) in 20 to 45 Year Old Chinese Women (V501-041)CompletedNCT00834106Phase 3Results posted
- An Open-Label, Single Dose Safety Study of Quadrivalent HPV Vaccine in Chinese Female Subjects (V501-035)CompletedNCT00635830Phase 1Results posted
- Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001)CompletedNCT00543543Phase 3Results posted
- An Immunogenicity and Safety Study of Gardasil® in Chinese Subjects (V501-030)(COMPLETED)CompletedNCT00496626Phase 3Results posted
- V501 Immunogenicity Study in Females Age 9 to 17 Years (V501-028)CompletedNCT00411749Phase 2Results posted
- Safety, Tolerability and Immunogenicity of HPV (Human Papilloma Virus) Vaccine in Healthy Females 9 to 15 Years of Age in India (V501-029)CompletedNCT00380367Phase 3Results posted
- V501 Efficacy Study in Women Aged 18 to 26 (V501-027)CompletedNCT00378560Phase 2Results posted
- Dose-Ranging Study of Quadrivalent Human Papillomavirus (HPV) (Types 6,11,16,18) L1 Virus-Like Particle (VLP) Vaccine (V501-007)(COMPLETED)CompletedNCT00365716Phase 2Results posted
- Human Papillomavirus (HPV) Registration Study (Gardasil)(V501-023)(COMPLETED)CompletedNCT00157950Phase 3Results posted
- A Study of Gardasil (V501) in Preadolescents and Adolescents (V501-018)CompletedNCT00092547Phase 3Results posted
- A Study to Evaluate the Safety, Immune Response, and Efficacy of Gardasil (V501, qHPV) in Mid-Adult Women (V501-019)CompletedNCT00090220Phase 3Results posted
- V503 in Chinese Girls 9-14 Years Old Versus Chinese Women 20-26 Years Old (V503-071)Active, not recruitingNCT05450705Phase 3
- Efficacy, Immunogenicity, and Safety of V503 in Chinese Males (V503-052)Active, not recruitingNCT05285826Phase 3
- Safety and Immunogenicity of Extended 2-dose Regimens of 9-valent Human Papillomavirus (9vHPV) Vaccine (V503-069)Active, not recruitingNCT04708041Phase 3
- Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049)Active, not recruitingNCT04199689Phase 3
- Efficacy, Immunogenicity and Safety of V503 in Chinese Women Aged 20-45 Years (V503-023)Active, not recruitingNCT03998254Phase 3
- Long-term Follow-up of Broad Spectrum Human Papillomavirus (HPV) Vaccine Study in Women (V503-021)Active, not recruitingNCT02653118
- Post-Licensure Study of the Safety of GARDASIL™ in Males (V501-070)CompletedNCT01567813
- GARDASIL™ Post Marketing Surveillance in the Philippines (V501-077)TerminatedNCT01355003
- Tolerability and Immunogenicity of Gardasil in Females Between 16 and 23 Years of Age in India (V501-034)WithdrawnNCT00733122Phase 3
- A Study to Evaluate Tolerability and Immunogenicity of V504 Administered Concomitantly With GARDASIL (V504-001)(COMPLETED)CompletedNCT00551187Phase 2
- Broad Spectrum HPV (Human Papillomavirus) Vaccine in 16 to 26 Year Old Women (V505-001)CompletedNCT00520598Phase 2